Anticoagulation in continuous renal replacement therapy.
Vargas Hein
O
O
Department of Anesthesiology and Intensive Care, University Hospital Charité, Campus Mitte, Berlin, Germany. ortrud.vargas@charite.de
Kox
W J
WJ
Spies
C
C
D058186:Acute Kidney Injury / Q000628:therapy*; D000925:Anticoagulants / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D002951:Citrates / Q000627:therapeutic use; D016638:Critical Illness; D003871:Dermatan Sulfate / Q000627:therapeutic use; D004338:Drug Combinations; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006497:Heparan Sulfate / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D011453:Prostaglandins / Q000627:therapeutic use; D017582:Renal Replacement Therapy / Q000379:methods; D000077559:Sodium Citrate
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D002951:Citrates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; D011453:Prostaglandins; D000077559:Sodium Citrate; C035838:danaparoid